Omalizumab improves efficacy of oral immunotherapy for multiple food allergies

Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

OIT [+]   

More #news: